Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study
Two dose levels of citalopram , 10–30 mg and 20–60 mg , were compared with imipramine , 50–150 mg , in depressed patients treated in general practice . This was a multicentre study carried out in Denmark , Sweden , Norway , and Finl and . The duration of treatment was 6 weeks with an optional continuation phase of a further 16 weeks . The patients were assessed by means of the Hamilton Rating Scale for Depression ( HAMD ) , Clinical Global Impressions ( CGI ) , and a visual analogue self-rating scale for depression . Observed and spontaneously reported adverse events were recorded . A total of 472 patients were entered into the study and 400 patients completed the 6 week trial period . A total of 297 patients completed the optional 22 week double-blind period . A clear reduction of the HAMD total scores was seen in all three treatment groups with no significant differences between groups . A reduction of the HAMD anxiety factor and sleep factor scores was also seen with no significant differences between treatments . The imipramine-treated patients showed a higher frequency of adverse events , especially the anti-cholinergic type , than citalopram-treated patients . Most patients entered into the continuation phase remained well
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .